Core Insights - Rafael Holdings, Inc. reported a net loss from continuing operations of $4.5 million for Q4 FY 2024, compared to a net gain of $1.3 million in the same period last year [3][6][19] - The company is advancing its strategy to develop clinical stage assets and has entered into a merger agreement with Cyclo Therapeutics, which is conducting a pivotal Phase 3 study for Trappsol® Cyclo™ [2][9] - For the full fiscal year 2024, Rafael Holdings recorded a net loss of $34.4 million, significantly higher than the $8.4 million loss in the previous year, primarily due to in-process research and development expenses related to the Cornerstone acquisition [6][19] Financial Performance - As of July 31, 2024, Rafael Holdings had cash, cash equivalents, and marketable securities totaling $65.9 million [3] - Research and development expenses for Q4 FY 2024 were $1.5 million, up from $1.3 million in the prior year, attributed to activities at Cornerstone and Day Three Labs [4] - General and administrative expenses for Q4 FY 2024 increased to $2.3 million from $1.4 million in the same period last year, mainly due to additional expenses from Cornerstone and Day Three Labs [5] Yearly Overview - For the fiscal year ended July 31, 2024, research and development expenses totaled $4.2 million, down from $6.3 million in the previous year due to the winding down of early-stage programs [7] - General and administrative expenses for the fiscal year remained flat at $8.9 million compared to the prior year, with increases from Cornerstone and Day Three Labs offsetting reductions at Rafael Holdings [8] - The company reported a significant in-process research and development expense of $89.9 million related to the Cornerstone acquisition during FY 2024 [6] Strategic Developments - The merger with Cyclo Therapeutics is expected to close in the coming months, with a shareholder vote anticipated [2] - Cyclo Therapeutics is fully enrolled in its pivotal Phase 3 study for Trappsol® Cyclo™, with interim results expected in mid-2025 [2] - Rafael Holdings holds a majority interest in several clinical and early-stage pharmaceutical companies, including LipoMedix Pharmaceuticals and Day Three Labs, focusing on addressing high unmet medical needs [9][10]

Core Points - CenterPoint Energy is actively preparing for potential impacts from Hurricane Rafael, which has intensified to a Category 3 storm with maximum sustained winds of 115 mph [1] - The company has suspended natural gas disconnections in Texas, Louisiana, and Mississippi to focus on emergency preparedness [4] - CenterPoint has mobilized over 13,000 mutual assistance resources to support emergency response efforts [1] Emergency Preparedness - Enhanced staffing plans and pre-landfall emergency protocols are being implemented to address potential impacts on electric and natural gas networks [1][3] - The company is coordinating with emergency responders and sharing safety information with customers across its Gulf Coast service area [2][3] Customer Safety Measures - CenterPoint encourages customers to take proactive safety measures and stay vigilant as the storm approaches [3][8] - Safety tips for electric customers include avoiding opening freezers and refrigerators unnecessarily, using generators safely, and reporting downed power lines [5][7] Communication and Updates - Customers are encouraged to enroll in the Power Alert Service® for real-time updates on outages and restoration efforts [7] - CenterPoint provides resources and safety tips on its website and through social media for ongoing updates [9][10]

Core Points - CenterPoint Energy is actively monitoring Tropical Storm Rafael and preparing for potential impacts across its service areas in Texas, Louisiana, and Mississippi [1][2][3] - The company has urged over 2.25 million natural gas customers in the affected regions to take proactive safety measures [1] - CenterPoint is coordinating with emergency partners and local, state, and federal officials to ensure a swift response and restoration of services post-storm [2][3] Company Preparedness - CenterPoint is preparing to deploy frontline crews to clear storm debris and repair system damage to restore electricity and natural gas services [3] - The company is sharing safety information with customers and encouraging them to take necessary precautions [2][7] - CenterPoint has established a Power Alert Service® for electric customers to receive updates on outages and restoration times [6] Safety Information - Customers are advised not to turn off natural gas service at the meter to prevent water from entering the lines during flooding [4] - In case of a natural gas smell, customers should evacuate the area and contact CenterPoint for assistance [4] - CenterPoint emphasizes the importance of knowing the location of natural gas meters and keeping debris away from them [5] Communication and Resources - CenterPoint encourages customers to follow their social media for real-time updates and visit their website for storm-related safety tips [8][7] - The company has been in operation for over 150 years, serving more than 7 million metered customers across multiple states [9]

Core Points - CenterPoint Energy is actively monitoring tropical developments and has activated emergency response plans in preparation for potential tropical storms or hurricanes [1][2] - The company has initiated the Greater Houston Resiliency Initiative to enhance grid resilience and reduce outage risks during the hurricane season [3][5] Phase One of Greater Houston Resiliency Initiative - In the first phase, CenterPoint installed over 1,100 stronger fiberglass poles, trimmed vegetation along more than 2,000 miles of power lines, and installed over 300 automation devices [4] Phase Two of Greater Houston Resiliency Initiative - The second phase includes significant actions to strengthen the energy system over the next eight months, aiming to complete work before the 2025 hurricane season [5] - Actions will lead to a self-healing grid, reducing outage minutes by over 125 million annually for customers in the Greater Houston area [6] - Specific plans include installing or replacing 25,000 poles, trimming or removing vegetation across 4,000 miles of power lines, and installing 4,500 automation devices [6] Customer Preparedness - Customers are encouraged to update emergency plans and prepare storm kits with essential items [7] - The company promotes enrollment in the Power Alert Service® for timely updates on outages and restoration [9] Outage Tracker Improvements - CenterPoint will provide estimated restoration times within 24 hours of a storm exiting the service area and will update these estimates daily [10]

Company Overview - Texas Instruments Incorporated (TI) is a global semiconductor company that designs, manufactures, and sells analog and embedded processing chips for various markets including industrial, automotive, personal electronics, communications equipment, and enterprise systems [3] Upcoming Event - Rafael Lizardi, Senior Vice President and Chief Financial Officer of TI, will speak at the Goldman Sachs 2024 Communacopia + Technology Conference on September 10, 2024, at 10:10 a.m. Pacific time [1] - The conference will include a Q&A session where Lizardi will address questions from analysts and investors, discussing TI's business outlook and strategies for key markets [1] Business Strategy - TI aims to leverage its analog and embedded processing technologies to position the company for growth in the semiconductor industry [1]

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they have entered into a definitive merger agreement to combine the two companie ...

Financial Performance - The Company reported a loss from operations of $92.8 million for the three months ended April 30, 2024, compared to a loss of $3.0 million for the same period in 2023, representing an increase of 2,943%[336] - Loss from operations for the nine months ended April 30, 2024, was $98.8 million, a significant increase of $86.4 million compared to the same period in 2023[350] - The Company has not generated any revenues from its Healthcare segment to date, with all expenses related to its investment companies[336] Research and Development - Research and development expenses for the three months ended April 30, 2024, were $1.2 million, a 64% increase from $740,000 in the same period in 2023[336] - Research and development expenses increased by $314 thousand for the nine months ended April 30, 2024, also due to the acquisition of Day Three[347] Acquisitions and Investments - The Company acquired 70 million ordinary shares of LipoMedix for approximately $2.1 million, increasing its ownership to 95%[327] - The Company raised $925,000 from third parties for a 31.62% ownership stake in Rafael Medical Devices as of August 2023[333] - The Company invested approximately $133.7 million in available-for-sale securities during the nine months ended April 30, 2024[363] - The total aggregate fair value of the investment in Cyclo Therapeutics Inc. was $15.2 million as of April 30, 2024[371] Revenue and Expenses - The Company recorded an IPR&D expense of $89.9 million for the three months ended April 30, 2024, compared to no such expense in the same period in 2023, marking a 100% increase[342] - Infusion Technology Revenue increased by $262 thousand for the nine months ended April 30, 2024, compared to the same period in 2023, attributed to the acquisition of Day Three[344] - Cost of Infusion Technology revenue rose by $85 thousand during the nine months ended April 30, 2024, due to the acquisition of Day Three, primarily related to supplies and production labor[345] - General and administrative expenses increased by $225 thousand for the nine months ended April 30, 2024, mainly due to the acquisition of Day Three[346] Cash Flow and Liquidity - As of April 30, 2024, the company held cash and cash equivalents of approximately $7.4 million, a decrease of 65% from $21.5 million as of July 31, 2023[360] - Working capital decreased by 18% from $80.8 million to $66.3 million during the same period[360] - Cash used in operating activities decreased by 44%, from $8.8 million for the nine months ended April 30, 2023, to $4.9 million for the same period in 2024[362] - Cash used in investing activities for the nine months ended April 30, 2024, was approximately $8.9 million, significantly lower than $34.4 million in the prior year, representing a 74% decrease[363] - The company does not anticipate paying dividends until achieving sustainable profitability and retaining certain minimum cash reserves[366] - The company expects its cash and available-for-sale securities to be sufficient to meet obligations for at least the next 12 months[361] Other Financial Metrics - Interest income decreased to $1.8 million for the nine months ended April 30, 2024, down from $2.3 million in the same period in 2023, primarily due to changes in market rates[350] - Recovery of receivables from Cornerstone Pharmaceuticals increased by approximately $31.3 million for the nine months ended April 30, 2024[355] - The company recorded a realized gain of approximately $1.5 million on available-for-sale securities for the nine months ended April 30, 2024, compared to $0.2 million in the same period in 2023[352] - The company recognized a loss of approximately $422 thousand from its ownership interest in Day Three for the nine months ended April 30, 2024[357] - The benefit from income taxes included approximately $2.6 million received from the sale of unused net operating loss carryforwards for the nine months ended April 30, 2024[356] Corporate Actions - The Company terminated its merger agreement with Cornerstone on February 2, 2022, following the failure of clinical trials for its lead product candidate[322]

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential NEWARK, NJ – June 14, 2024 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. "During fiscal 2024, we have continued to develop our existing portfolio w ...

Core Viewpoint - Rafael Holdings continues to develop its portfolio while exploring strategic investment opportunities, with a focus on advancements in biotechnology and cannabis products [1][17]. Financial Performance - For the three months ended April 30, 2024, the company reported a net loss from continuing operations of $32.4 million, or $1.36 per diluted share, compared to a net loss of $1.4 million, or $0.06 per diluted share, in the same period last year [13]. - For the nine months ended April 30, 2024, the net loss from continuing operations was $29.9 million, or $1.26 per diluted share, compared to a net loss of $9.6 million, or $0.42 per diluted share, in the prior year [15]. - Research and development expenses for the three months ended April 30, 2024, were $1.5 million, up from $0.7 million in the previous year, primarily due to new activities at Cornerstone and Day Three Labs [2]. - For the nine months ended April 30, 2024, research and development expenses totaled $2.6 million, down from $5.0 million in the prior year, reflecting the winding down of early-stage programs [4]. Investments and Assets - As of April 30, 2024, the company had cash, cash equivalents, and marketable securities amounting to $72.4 million [1]. - The total assets of Rafael Holdings were reported at $101.6 million as of April 30, 2024, compared to $98.8 million as of July 31, 2023 [8][20]. - The company holds significant investments in Cyclo Therapeutics, with an investment value of $15.2 million as of April 30, 2024, compared to $4.8 million in the previous year [8]. Strategic Developments - Cyclo Therapeutics has completed enrollment in its pivotal Phase 3 study for Trappsol® Cyclo™ aimed at treating Niemann-Pick Disease Type C1, a rare genetic disorder [1]. - Day Three Labs has begun generating revenue by innovating cannabis products with pharmaceutical-grade technology, enhancing product quality and predictability [1][17]. - The company has increased its investment in Day Three Labs, now holding a majority interest of 79% [13][15].

☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended January 31, 2024. or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-55863 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Address of principal executive offices, zip code) | (212) 658-1450 | | --- | (Registrant's telephone number, including area code) Securities registered pursuant ...